Why Abzena?
Trust our focused approach.
At Abzena we tailor our antibody discovery services to your needs. We deliver expert assessments of target molecules, immunization strategies and antibody screening cascades.
We apply innovative approaches and equipment to generate robust data that ensures optimal antibody discovery and supports the selection of the best antibody candidates for your drug development program.
Our Hybridoma MAX™ custom mouse monoclonal antibody discovery service maximizes the number of antibodies discovered through a dual, high-throughput screening platform that creates more candidates for development.
Abzena & Mabqi have formed a strategic partnership that will integrate Mabqi’s antibody discovery capabilities with Abzena’s development and manufacturing services, offering biopharma customers a more streamlined, end-to-end drug development solution.
The partnership’s combined offerings will leverage Mabqi’s LiteMab Antibody Discovery Studio for hit screening, characterization, and hit selection by using universal & pH-sensitive libraries to identify top lead candidates, and utilize Abzena’s capabilities for developability, cell line development, process development, and GMP manufacturing.
Our antibody discovery methods ensure high affinity antibodies and where required cross-reactivity with the target, and include:
Having a 100% accurate sequence is crucial. Especially true if your antibody sequence is to be used for downstream activities such as recombinant antibody production or antibody humanization. Unlike some methods that can introduce mutations at the start, by using primers specifically designed to bind in the leader sequence, Abzena can determine the authentic start to an antibody variable domain. This simple difference can be critical to determining the sequence of a fully functional antibody.
Our team of antibody & protein engineering experts are well equipped to enhance and de-risk your program’s lead candidate through early development. Abzena have over 20 years of experience in antibody design and protein engineering at our Cambridge facility, and strive to reduce uncertainties in your project, maximizing the likelihood of success. By integrating advanced protein engineering knowledge with cutting-edge analytical techniques, we are able to create optimal drug candidates.
The leading biologics CDMO + CRO that de-risks and accelerates drug development. Let’s move medicine forward for patients in need.